WO2001042204A1 - Composes sulfamides aromatiques phenyle ou benzyle n-substitues et leurs applications - Google Patents
Composes sulfamides aromatiques phenyle ou benzyle n-substitues et leurs applications Download PDFInfo
- Publication number
- WO2001042204A1 WO2001042204A1 PCT/CN2000/000187 CN0000187W WO0142204A1 WO 2001042204 A1 WO2001042204 A1 WO 2001042204A1 CN 0000187 W CN0000187 W CN 0000187W WO 0142204 A1 WO0142204 A1 WO 0142204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- aromatic
- compounds
- benzyl
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Definitions
- the present invention relates to N-substituted benzyl or aromatic sulfonamide compounds, that is, N- (3,5-bis-disubstitutedcarbamyl 4-hydroxy) benzyl (or aromatic sulfonamide compounds and physiologically acceptable salts thereof.
- Li Liangquan et al. Reported the synthesis of tacroline i and its antiarrhythmic activity (Li Liangquan et al., Chinese Science, 1997, 7, 723; Yinzhou et al., Journal of Pharmaceutical Sciences, 1979, 14, 710). Phase ⁇ The chemical structure of tacroline is studied and its physiological activity has been studied (Sun Cun ', Chinese Journal of Pharmaceutical Sciences, 1981, 16. 564; 1986, 21, 692; Lin Mulan et al., Chinese Journal of Pharmaceutical Sciences, 1982, 17, 212; DM , St our et al. J. Med. Qiem., 1983, 26, 808; 1984, 27, 1347; 1985, 28, 295; 1989, 32, 1910; RJ Chorvat et al., J. Med. Chem., 1993, 36, 2494.).
- tamoxaline is a completely antiarrhythmic drug, it can be given to patients with arrhythmia, and the ventricular premature beat can disappear in 2 to 3 days. Intravenous injection or infusion can significantly reduce ventricular premature beats, ventricular tachycardia, and even disappear. However, after oral administration for more than one month, the patient's skin had reversible pigmentation, which gradually subsided after stopping the drug. This is related to the oxidation of certain groups of quinololine in the skin or instability in the liquid.
- the purpose of the present invention is to find a new class of drugs that are effective against tacroline and can overcome the shortcomings of tacroline.
- a class of N-substituted benzyl or * S aromatic sulfonamide compounds has the general formula:
- ⁇ Qianhe County substituted by alkyl, alkoxy, nitro, halogen, substituted amino
- the preparation steps are:
- Compound ⁇ can be prepared from Mannich reaction of substituted aminophenol with formaldehyde and secondary amine
- Compound B — 87823 can significantly reduce ventricular premature beats (3 ⁇ 43 ⁇ 4 rate 77%), inhibit the incidence of ventricular tachycardia by 73%, and the incidence of ventricular premature beats inhibited by normorline is 50%.
- Compound ⁇ 87823 can also counteract ectopic rhythm of guinea pig papillary muscle induced by aconitine (Chen Hongzhuan et al., Journal of Shanghai Second Medical University, 1989, 9, 105). Test negative for Ames. See Table 3 for pharmacological effects of each compound.
- louM 10 101 ⁇ 2 The prevention index and treatment index in Table 3 are acute toxicity tests in rats.
- the half lethal dose (LD 5 ) is calculated, and the rat aconitine arrhythmia is used to calculate the anti-arrhythmic effect. 50 )!
- Therapeutic tests find an effective amount (ED). Then take LD 5 .
- the value of ED 50 is taken as the prevention index, LD 5 .
- the value of ED is used as a therapeutic index »To examine the antiarrhythmic properties of these compounds From Table 3 it can be seen that the B-87823 salt « has the highest prevention and treatment index.
- the present invention is illustrated by the following preparation examples, but the present invention is not limited thereto.
- B-86835 was also prepared by the above steps.
- N_ [3, 5-bis (1-pyrrolemethyl) -4-hydroxy] benzyl-4-chlorochlorosulfonamide B-87829) 1.
- ⁇ ethylamine (0.77ml)
- p-chlorobenzenesulfonyl chloride 1.2g.
- the reaction mixture was stirred at room temperature for 4 hours, the solvent was distilled off under reduced pressure. The residual solid was washed with water and recrystallized from ethanol to obtain N- (4-hydroxybenzyl) -p-chlorobenzenesulfonamide (1.2g), mp 187-189 ° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/149,236 US6605635B1 (en) | 1999-12-10 | 2000-07-03 | N-substituted benzyl or phenyl aromatic sulfamides compounds and the use thereof |
AT00941870T ATE314345T1 (de) | 1999-12-10 | 2000-07-03 | N-substituierte benzyl oder phenyl arylsulfamide und ihre verwendung |
JP2001543505A JP4015853B2 (ja) | 1999-12-10 | 2000-07-03 | N−置換ベンジルまたはフェニル芳香族スルホンアミド化合物及びその用途 |
EP00941870A EP1245561B1 (en) | 1999-12-10 | 2000-07-03 | N-substituted benzyl or phenyl aromatic sulfamides compounds and the use thereof |
DE60025270T DE60025270T2 (de) | 1999-12-10 | 2000-07-03 | N-substituierte benzyl oder phenyl arylsulfamide und ihre verwendung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB99124236XA CN1172908C (zh) | 1999-12-10 | 1999-12-10 | N-取代苄基或苯基芳香磺酰胺化合物及其用途 |
CN99124236.X | 1999-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001042204A1 true WO2001042204A1 (fr) | 2001-06-14 |
Family
ID=5283321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2000/000187 WO2001042204A1 (fr) | 1999-12-10 | 2000-07-03 | Composes sulfamides aromatiques phenyle ou benzyle n-substitues et leurs applications |
Country Status (7)
Country | Link |
---|---|
US (1) | US6605635B1 (zh) |
EP (1) | EP1245561B1 (zh) |
JP (1) | JP4015853B2 (zh) |
CN (1) | CN1172908C (zh) |
AT (1) | ATE314345T1 (zh) |
DE (1) | DE60025270T2 (zh) |
WO (1) | WO2001042204A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112638903A (zh) * | 2019-01-29 | 2021-04-09 | 沪亚生物国际有限责任公司 | 舒欣啶盐 |
US11364223B2 (en) | 2018-12-13 | 2022-06-21 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
KR102697726B1 (ko) | 2019-01-29 | 2024-08-21 | 후야바이오 인터내셔널, 엘엘씨 | 설카딘 염 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6913639B2 (en) * | 2000-12-15 | 2005-07-05 | Surface Specialties, S.A. | Surface functionalization of pigments and/or dyes for radiation curable ink printing and coating applications |
JP6116907B2 (ja) * | 2009-11-17 | 2017-04-19 | フヤ バイオサイエンス インターナショナル エルエルシー | サルカルディン及びその塩の緩速点滴 |
DK3311810T3 (da) * | 2009-11-17 | 2022-10-24 | Huyabio Int Llc | Anvendelse af sulcardin til behandling af atrieflimmer |
US10973780B2 (en) | 2019-05-15 | 2021-04-13 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
AU2021288056A1 (en) * | 2020-06-12 | 2023-02-09 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
CA3198795A1 (en) | 2020-11-18 | 2022-05-27 | Jeffrey Becker | Complexing agent salt formulations of pharmaceutical compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5059620A (en) * | 1985-12-27 | 1991-10-22 | The Du Pont Merck Pharmaceutical Company | Aryl substituted aminomethyl benzene derivatives |
-
1999
- 1999-12-10 CN CNB99124236XA patent/CN1172908C/zh not_active Expired - Lifetime
-
2000
- 2000-07-03 EP EP00941870A patent/EP1245561B1/en not_active Expired - Lifetime
- 2000-07-03 US US10/149,236 patent/US6605635B1/en not_active Expired - Lifetime
- 2000-07-03 DE DE60025270T patent/DE60025270T2/de not_active Expired - Lifetime
- 2000-07-03 WO PCT/CN2000/000187 patent/WO2001042204A1/zh active IP Right Grant
- 2000-07-03 JP JP2001543505A patent/JP4015853B2/ja not_active Expired - Lifetime
- 2000-07-03 AT AT00941870T patent/ATE314345T1/de not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5059620A (en) * | 1985-12-27 | 1991-10-22 | The Du Pont Merck Pharmaceutical Company | Aryl substituted aminomethyl benzene derivatives |
Non-Patent Citations (1)
Title |
---|
DAVID M. STOUT ET AL.: "Synthesis and antiarrhythmic and parasympotholytic properties of substituted phenols. 3 Modifications to the linkage region (region 3)", J. MED. CHEM., vol. 28, no. 3, 1985, pages 295 - 298, XP002956928 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364223B2 (en) | 2018-12-13 | 2022-06-21 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
CN112638903A (zh) * | 2019-01-29 | 2021-04-09 | 沪亚生物国际有限责任公司 | 舒欣啶盐 |
US11020374B2 (en) | 2019-01-29 | 2021-06-01 | Huya Bioscience International, Llc | Sulcardine salts |
KR20210130157A (ko) * | 2019-01-29 | 2021-10-29 | 후야 바이오사이언스 인터내셔널 엘엘씨 | 설카딘 염 |
KR102405199B1 (ko) | 2019-01-29 | 2022-06-02 | 후야 바이오사이언스 인터내셔널 엘엘씨 | 설카딘 염 |
KR20220079688A (ko) * | 2019-01-29 | 2022-06-13 | 후야 바이오사이언스 인터내셔널 엘엘씨 | 설카딘 염 |
US11426382B2 (en) | 2019-01-29 | 2022-08-30 | Huyabio International, Llc | Sulcardine salts |
KR102697726B1 (ko) | 2019-01-29 | 2024-08-21 | 후야바이오 인터내셔널, 엘엘씨 | 설카딘 염 |
Also Published As
Publication number | Publication date |
---|---|
EP1245561A1 (en) | 2002-10-02 |
DE60025270D1 (de) | 2006-02-02 |
EP1245561A4 (en) | 2003-04-23 |
CN1299813A (zh) | 2001-06-20 |
JP2003516385A (ja) | 2003-05-13 |
EP1245561B1 (en) | 2005-12-28 |
DE60025270T2 (de) | 2006-08-17 |
CN1172908C (zh) | 2004-10-27 |
US6605635B1 (en) | 2003-08-12 |
ATE314345T1 (de) | 2006-01-15 |
JP4015853B2 (ja) | 2007-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR122017023795B1 (pt) | Metodo para preparaqao de composiçao farmaceutica | |
CN112566909B (zh) | 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途 | |
IE49701B1 (en) | Amides of acyl-carnitines,process for preparing same and pharmaceutical compositions containing such amides | |
JPH06509820A (ja) | 選択的ホスホジエステラーゼ■阻害剤としての三置換フェニル誘導体 | |
JP2002509908A (ja) | アミノシクロヘキシルエーテル化合物およびその用途 | |
OA12631A (fr) | Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés. | |
BR0215777B1 (pt) | Composition, method for preparing the same, pharmaceutical composition for preventing and treating cardioischemia, cerebrosis, cerebral arterial oclusion and for improving micro-circulation of the brain, and use of compound | |
EP0375726A1 (en) | Melatonin analogues | |
WO2001042204A1 (fr) | Composes sulfamides aromatiques phenyle ou benzyle n-substitues et leurs applications | |
BR112016020556B1 (pt) | Compostos, composição farmacêutica e uso de um composto | |
SU1591805A3 (ru) | Способ получения производного сульфонамцца | |
WO2020228789A1 (zh) | 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途 | |
CA3140231C (en) | 3-aryloxyl-3-five-membered heteroaryl-propylamine compound, and crystal form and use thereof | |
PT78491B (en) | Process for the preparation of new 5-acyl-2-(1h)-pyridinones useful as cardiotonic agents | |
DK168992B1 (da) | Indanderivater, en fremgangsmåde til deres fremstilling og lægemidler med indhold deraf | |
JPS6183147A (ja) | 新規なアミノアルコール誘導体およびその製造法並びにそれを有効成分とするグルタミン酸遮断剤 | |
DK2603486T3 (en) | Panthenyldocosahexaenoate and its use in the treatment and prevention of cardiovascular diseases | |
JPH0471067B2 (zh) | ||
JPH09169755A (ja) | ベンゾ[b]フランから得られたケトンのアミジノヒドラゾン類、それらの製造方法、およびこれらの化合物を含有する医薬 | |
AU2017239419B2 (en) | Benzenesulfonyl-asymmetric ureas and medical uses thereof | |
JPS60116678A (ja) | n‐プロパノールアミン誘導体エーテル | |
JPS63500796A (ja) | アミノシクロアルキルアミドの抗不整脈剤用途 | |
CN102757444A (zh) | 具有一氧化氮供体性质的苯并呋喃类化合物 | |
JP2002511451A (ja) | アザシクロアルカン誘導体、その製造及び治療上の使用 | |
US3988454A (en) | Phenylalkylaralkylamines for pharmaceutical use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10149236 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 543505 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000941870 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000941870 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000941870 Country of ref document: EP |